biotechnology Archives – Cambridge Enterprise

T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic

13 November 2025 • 3 min read

CardiaTec Biosciences - cardiovascular biology

CardiaTec Biosciences

22 April 2025 • 3 min read

BioTryp Therapeutics: Biofilm-Inhibiting Technology

BioTryp Therapeutics

17 March 2025 • 2 min read

BioTryp Therapeutics Raises Pre Seed Funding - anti-biofilm

BioTryp Therapeutics raises pre-seed funding

15 August 2024 • 4 min read

Colourful x-ray image of a human heart and arteries in a chest, illustrated with a blue background and red gradients for the heart

Morphogen-IX raises £18.4m in Series B financing

18 December 2018 • 3 min read

Colourful x-ray image of a human heart and arteries in a chest, illustrated with a blue background and red gradients for the heart

Spin-out Morphogen-IX announces its clinical development candidate

27 November 2018 • 2 min read

Seed Fund Investment Manager on BioBeat’s 2018 list of 50 Female Movers and Shakers

01 November 2018 • 6 min read

Cambridge Enterprise licenses IP to produce platelets from stem cells

15 December 2016 • 3 min read

New programme to help Cambridge researchers connect with industry

22 March 2012 • 2 min read

Astex announces milestone in oncology collaboration

12 January 2011 • 1 min read

Highly successful year for Cambridge Enterprise

24 March 2010 • 2 min read

CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda

04 March 2010 • 3 min read